复发性心包炎患者从口服治疗转为利洛纳塞单药治疗
RHAPSODY试验事后分析纳入86例复发性心包炎患者,评估从口服多药方案转为IL-1阻断剂利洛纳塞单药治疗的可行性。基线64%患者使用多药方案,平均7.9周转为单药且无复发,结论提示快速停用口服治疗可行。
要点
- 复发性心包炎患者平均7.9周可转为利洛纳塞单药,无复发。
- 64%患者基线使用多药方案,包括NSAIDs联合秋水仙碱等。
- 秋水仙碱联合糖皮质激素患者无论序贯或同期减停,中位7.7–8.0周转单药。
核心结论
- 在转为利洛纳塞单药期间快速停用口服复发性心包炎治疗是可行的,且未触发心包炎复发。
研究设计与样本
- RHAPSODY为多中心(澳大利亚、以色列、意大利、美国)双盲、安慰剂对照、随机撤药试验,纳入成人和青少年复发性心包炎患者。
- 本分析为事后分析,研究者在12周导入期启动利洛纳塞并停用口服心包炎治疗,随机化患者接受研究药物单药治疗。
- 在基线接受多药方案且导入期达到利洛纳塞单药治疗的患者中,量化至单药治疗的时间。
主要发现
- 86例入组患者中,平均至利洛纳塞单药治疗时间为7.9周,无复发。
- 64%(n=55)患者基线接受多药方案:NSAIDs联合秋水仙碱占44%(24/55),秋水仙碱联合糖皮质激素占24%(13/55),NSAIDs、秋水仙碱联合糖皮质激素占33%(18/55)。
- 基线接受秋水仙碱和糖皮质激素的患者,无论序贯(n=14;中位7.7周)或同期(n=17;中位8.0周)减停,均转为利洛纳塞单药且无复发。
- 至单药治疗的中位时间与糖皮质激素剂量和疗程相似:≤15 mg/天(n=21)为7.3周;>15 mg/天(n=18)为8.0周;长期(≥28天)为7.6周。
临床怎么用
- 对于复发性心包炎患者,在启动利洛纳塞期间可考虑快速停用口服多药方案,包括秋水仙碱和糖皮质激素。
- 糖皮质激素减停方式(序贯或同期)及剂量(≤15 mg/天或>15 mg/天)不影响转为利洛纳塞单药的时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Polypharmacy management of recurrent pericarditis (RP) often involves long-term therapies, often with negative effects. Slow tapering of oral therapies is often required to avoid recurrence. A post hoc analysis of the phase III trial Rilonacept inHibition of interleukin-1 Alpha and beta for recurrent Pericarditis: a pivotal Symptomatology and Outcomes Study (RHAPSODY) evaluated investigator approaches to transitioning to IL-1 blockade monotherapy with rilonacept, which was hypothesised to allow accelerated withdrawal of common multidrug pericarditis regimens. METHODS: RHAPSODY was a multicentre (Australia, Israel, Italy, USA), double-blind, placebo-controlled, randomised-withdrawal trial in adults and adolescents with RP. Investigators initiated rilonacept at the labelled dose level and discontinued oral pericarditis therapies during the 12-week run-in; randomised patients received study drug as monotherapy. Time to rilonacept monotherapy was quantified in patients receiving multidrug regimens at baseline who achieved rilonacept monotherapy during run-in. RESULTS: In 86 enrolled patients, mean time to rilonacept monotherapy was 7.9 weeks, with no recurrences. Of these, 64% (n=55) entered on multidrug regimens: non-steroidal anti-inflammatory drugs (NSAIDs) plus colchicine (44% (24/55)), colchicine plus glucocorticoids (24% (13/55)), or NSAIDs, colchicine, plus glucocorticoids (33% (18/55)). Investigators transitioned patients receiving colchicine and glucocorticoids at baseline to rilonacept monotherapy without recurrence regardless of taper approach: sequential (n=14; median, 7.7 weeks) or concurrent (n=17; median, 8.0 weeks). Median time to rilonacept monotherapy was similar regardless of glucocorticoid dose and duration: ≤15 mg/day (n=21): 7.3 weeks; >15 mg/day (n=18): 8.0 weeks; long-term (≥28 days): 7.6 weeks. CONCLUSIONS: Rapid discontinuation of oral RP therapies while transitioning to rilonacept monotherapy was feasible without triggering pericarditis recurrence. TRIAL REGISTRATION NUMBER: NCT03737110.
引用
- Brucato A, Wheeler A, Luis SA, et al. Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis. Heart. 2023. PMID: 36316102. doi:10.1136/heartjnl-2022-321328
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。